Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays
- PMID: 29857275
- DOI: 10.1016/j.ejmech.2018.05.035
Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays
Abstract
The Hedgehog (Hh) signaling pathway plays a critical role in controlling patterning, growth and cell migration during embryonic development. Aberrant activation of Hh signaling has been linked to tumorigenesis in various cancers, such as basal cell carcinoma (BCC) and medulloblastoma. As a key member of the Hh pathway, the Smoothened (Smo) receptor, a member of the G protein-coupled receptor (GPCR) family, has emerged as an attractive therapeutic target for the treatment and prevention of human cancers. The recent determination of several crystal structures of Smo in complex with different antagonists offers the possibility to perform structure-based virtual screening for discovering potent Smo antagonists with distinct chemical scaffolds. In this study, based on the two Smo crystal complexes with the best capacity to distinguish the known Smo antagonists from decoys, the molecular docking-based virtual screening was conducted to identify promising Smo antagonists from ChemDiv library. A total of 21 structurally novel and diverse compounds were selected for experimental testing, and six of them exhibited significant inhibitory activity against the Hh pathway activation (IC50 < 10 μM) in a GRE (Gli-responsive element) reporter gene assay. Specifically, the most potent compound (compound 20: 47 nM) showed comparable Hh signaling inhibition to vismodegib (46 nM). Compound 20 was further confirmed to be a potent Smo antagonist in a fluorescence based competitive binding assay. Optimization using substructure searching method led to the discovery of 12 analogues of compound 20 with decent Hh pathway inhibition activity, including four compounds with IC50 lower than 1 μM. The important residues uncovered by binding free energy calculation (MM/GBSA) and binding free energy decomposition were highlighted and discussed. These findings suggest that the novel scaffold afforded by compound 20 can be used as a good starting point for further modification/optimization and the clarified interaction patterns may also guide us to find more potent Smo antagonists.
Keywords: Antagonist; Molecular docking; Smoothened receptor; Virtual screening.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Structural optimization on a virtual screening hit of smoothened receptor.Eur J Med Chem. 2019 Jun 15;172:1-15. doi: 10.1016/j.ejmech.2019.03.057. Epub 2019 Mar 26. Eur J Med Chem. 2019. PMID: 30939349
-
Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.Eur J Med Chem. 2015 Jan 7;89:721-32. doi: 10.1016/j.ejmech.2014.11.006. Epub 2014 Nov 4. Eur J Med Chem. 2015. PMID: 25462278
-
Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.Eur J Pharmacol. 2015 Oct 5;764:220-227. doi: 10.1016/j.ejphar.2015.05.062. Epub 2015 Jun 3. Eur J Pharmacol. 2015. PMID: 26048307
-
Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.Future Med Chem. 2018 Dec;10(24):2855-2875. doi: 10.4155/fmc-2018-0200. Epub 2018 Dec 17. Future Med Chem. 2018. PMID: 30557039 Review.
-
Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.Cells. 2018 Dec 14;7(12):272. doi: 10.3390/cells7120272. Cells. 2018. PMID: 30558232 Free PMC article. Review.
Cited by
-
Structure-Activity Relationship Studies of Hydantoin-Cored Ligands for Smoothened Receptor.ChemistryOpen. 2021 Oct;10(10):1028-1032. doi: 10.1002/open.202100216. ChemistryOpen. 2021. PMID: 34648230 Free PMC article.
-
ImmtorLig_DB: repertoire of virtually screened small molecules against immune receptors to bolster host immunity.Sci Rep. 2019 Feb 28;9(1):3092. doi: 10.1038/s41598-018-36179-5. Sci Rep. 2019. PMID: 30816123 Free PMC article.
-
Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.Cell Death Dis. 2019 Jun 24;10(7):493. doi: 10.1038/s41419-019-1735-6. Cell Death Dis. 2019. PMID: 31235688 Free PMC article.
-
Ligand-based 3D pharmacophore modeling, virtual screening, and molecular dynamic simulation of potential smoothened inhibitors.J Mol Model. 2023 Apr 17;29(5):143. doi: 10.1007/s00894-023-05532-5. J Mol Model. 2023. PMID: 37062794
-
The Role of Smoothened in Cancer.Int J Mol Sci. 2020 Sep 18;21(18):6863. doi: 10.3390/ijms21186863. Int J Mol Sci. 2020. PMID: 32962123 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous